Literature DB >> 18532998

Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans.

L Bodin, J Perdu, M Diry, M-H Horellou, M-A Loriot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18532998     DOI： 10.1111/j.1538-7836.2008.03049.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  15 in total

1.  Novel insight into the mechanism of the vitamin K oxidoreductase (VKOR): electron relay through Cys43 and Cys51 reduces VKOR to allow vitamin K reduction and facilitation of vitamin K-dependent protein carboxylation.

Authors:  Mark A Rishavy; Aisulu Usubalieva; Kevin W Hallgren; Kathleen L Berkner
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

Review 2.  Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Houda Hachad; Yuan Ji; Lisa V Kalman; Reynold C Ly; Ann M Moyer; Stuart A Scott; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2020-05-04       Impact factor: 5.568

3.  Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction.

Authors:  Daniel Kurnik; Husam Qasim; Sophie Sominsky; Aharon Lubetsky; Noa Markovits; Chun Li; C Michael Stein; Hillel Halkin; Eva Gak; Ronen Loebstein
Journal:  Thromb Haemost       Date:  2012-08-07       Impact factor: 5.249

4.  CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Authors:  Stuart A Scott; Malgorzata Jaremko; Steven A Lubitz; Ruth Kornreich; Jonathan L Halperin; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

5.  Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.

Authors:  S A Lubitz; S A Scott; E B Rothlauf; A Agarwal; I Peter; D Doheny; S Van Der Zee; M Jaremko; C Yoo; R J Desnick; J L Halperin
Journal:  J Thromb Haemost       Date:  2010-02-02       Impact factor: 5.824

6.  Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.

Authors:  J-K Tie; D-Y Jin; K Tie; D W Stafford
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

7.  Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.

Authors:  Michael R Langley; Jessica K Booker; James P Evans; Howard L McLeod; Karen E Weck
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

8.  Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu.

Authors:  Xuejie Chen; Da-Yun Jin; Darrel W Stafford; Jian-Ke Tie
Journal:  Blood       Date:  2018-08-08       Impact factor: 22.113

9.  VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.

Authors:  Mohamed Hossam A Shahin; Larisa H Cavallari; Minoli A Perera; Sherief I Khalifa; Anne Misher; Taimour Langaee; Shitalben Patel; Kimberly Perry; David O Meltzer; Howard L McLeod; Julie A Johnson
Journal:  Thromb Haemost       Date:  2013-03-21       Impact factor: 5.249

Review 10.  Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.

Authors:  Andrea L Jorgensen; Richard J FitzGerald; James Oyee; Munir Pirmohamed; Paula R Williamson
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.